Skip to main content
Download PDF

Significance of Fib4 index as an indicator of alcoholic hepatotoxicity in health examinations among Japanese male workers: a cross-sectional and retrospectively longitudinal study

European Journal of Medical Research volume 28, Article number: 31 (2023) Cite this article

Abstract

Background

Fib4 index (Fib4) is clinically used as a noninvasive marker of liver fibrosis. In this study, we aimed to preliminarily investigate whether Fib4 can be used to detect individuals who need assessment for alcoholic liver disease (ALD) in the general population by clarifying the detailed association of Fib4 with alcohol consumption and gamma-glutamyl transferase (GGT) among male workers.

Methods

We analyzed data sets on the comprehensive medical examinations of male workers as cross-sectional and retrospectively longitudinal studies. We enrolled 10 782 males (mean age: 52.2 ± 10.2 years) in FY2019 and 7845 males (mean follow-up: 12.6 ± 6.7 years) who could be consecutively followed up for 20 years from FY2000 to FY2019. Data were evaluated using logistic regression and COX proportional analysis.

Results

In the cross-sectional setting, the rate of Fib4 ≥ 2.67 in heavy drinkers (≥ 40 g of ethanol/day) was increased dose dependently in those over 65 years old, and that of body mass index ≥ 30 kg/m2 was increased in those over 60 years old, but not in those with fatty liver. The odds ratio (OR) (95% confidence interval [CI]) for heavy drinking was 4.30 (95% CI = 1.90–9.72), and GGT ≥ 200 IU/L was considerably high (OR = 29.05 [95% CI = 17.03–49.56]). In the longitudinal setting, heavy drinkers and those with GGT ≥ 200 IU/L at 10 years after the baseline showed an increased risk for Fib4 ≥ 2.67 (hazard ratio = 2.17 [95% CI = 1.58–2.98] and 7.65 [95% CI 5.26–11.12], respectively).

Conclusions

The development of Fib4 ≥ 2.67 after 10 years was associated with heavy alcohol drinking and GGT level ≥ 200 IU/L. Therefore, Fib4 combined with GGT could indicate high risk of ALD. However, clinical examinations and course observations are essentially needed.

Background

The Fib4 index (Fib4) proposed by Sterling et al. has been developed as a simple index of liver fibrosis that can be calculated by adding platelets to age, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) [1]. Recently, nonalcoholic fatty liver disease (NAFLD) has become a major concern in not only liver disease but also metabolic syndrome and cardiovascular events [2]. NAFLD is divided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) [3]. Given that patients with NASH are at risk of developing liver fibrosis to hepatocellular carcinoma (HCC), Fib4 is recommended as a clinical marker for easily assessing the degree of progression of liver fibrosis in patients with NAFLD [4].

In the clinical setting of NAFLD management, Fib4 is popularly used by hepatologists [5], and several studies applied Fib4 in the general population [6, 7]. Regarding workers’ health examinations in Japan, blood count tests only collect data on red blood cells in order to assess anemia. In contrast, platelet (and white blood cells) counts are typically estimated automatically in blood count tests, excluding information that could be clinically important. Consequently, the current study was aimed to capitalize on this platelet data among Japanese workers. Originally, Fib4 was developed as a marker of fibrosis caused by hepatitis C [1] and was subsequently associated with viral hepatitis. However, liver fibrosis is not simply caused by viral hepatitis or NASH. Fib4 changes can be caused by other liver disorders, including alcoholic liver disease (ALD), considering that 27% of deaths caused by cirrhosis or chronic liver disease were reported to be linked to ALD [6]. Patients with ALD exhibit increased AST/ALT ratio, markedly increased gamma-glutamyl transferase (GGT), decreased cholinesterase, increased fibrosis marker, and decreased PT levels [8].

Symptoms are unlikely to appear unless ALD progresses [8]. Thus, detecting individuals who are at an early stage of ALD is necessary. ALD occurs in individuals with long-term excessive drinking, that is, drinking beverages containing ≥ 60 g of ethanol per day for ≥ 5 years [9]. However, Corrao et al. reported that people consuming 25 g of ethanol per day have a significantly increased risk for liver cirrhosis compared with abstainers [10]. Given that heavy drinkers frequently claim less alcohol consumption [11, 12], objective evaluation by hearing from a third party (family, friends, work colleagues, etc.) is also required. However, hearing from the family is usually difficult during medical examination, the GGT level is used as a popular marker of alcohol consumption in some populations [13, 14]

The pathological progression of NASH and ALD is similarly thought to be mediated by reactive oxygen species [15]. However, Fib4 as an effect marker of liver damage by alcoholic consumption among the general population remains unconfirmed. Therefore, to preliminarily investigate the significance of Fib4 in the general population in detecting patients that need assessment for ALD, we clarified the detailed association of Fib4 with alcohol consumption and GGT by using cross-sectional and longitudinal methods with 20 years of follow-up period.

Methods

Subjects

This study was conducted at a health center affiliated to a group of large-scale companies. Employees and their spouses from approximately 30 affiliated companies (30,000 employees) freely selected the timing and health center for their comprehensive health examinations. Details were described previously [16,17,18,19,20]. In the present study, we analyzed two data sets of comprehensive medical examinations as cross-sectional and longitudinal studies in the following years, from fiscal year (FY), which starts from April in Japan, 2000 to FY2019. First, we obtained the most current data of 15,792 examinees at FY2019, consisting of 13,700 males and 2092 females (mean age ± standard deviation [SD] = 53.0 ± 10.0). Second, 16,408 examiners (males = 13,701 and females = 2707; mean age = 47.8 ± 9.2 years) at FY2000 were obtained as the baseline and were followed up yearly until FY2019.

Due to the small number of females available for follow-up and their lower drinking habits, only men were enrolled in this study. To identify liver dysfunction-associated factors, such as ALT and AST, among 13,700 male examinees at FY2019, we established data set-1 (mean age ± SD = 53.1 ± 10.3), which included 12,918 examinees. Those with a present or past history of malignancy, hepatitis, dyslipidemia, positive HBsAg, or positive HCVAb were excluded. We excluded examinees with a present or past history of malignancy because some anticancer drugs may affect the platelet count. We also excluded those with a present illness of dyslipidemia because we preliminarily found possible associations between HDL or LDL and Fib4. We defined dyslipidemia as a person who is taking medication for dyslipidemia. In the longitudinal analysis, out of 13,459 male examinees at FY2000, 7845 were consecutively examined until FY2019, constituting the data set-2 (mean age ± SD = 46.7 ± 8.4), which had a mean follow-up period of 12.1 ± 6.0 (SD) years. Figure 1 presents the diagrams of the data sets.

Fig. 1
figure 1

Data set diagram. A Cross-sectional data set. B Follow-up data set

Full size image

Information on the present and/or past history of illness, smoking, and alcohol drinking was obtained using a health questionnaire. Total amount of alcohol consumption was calculated using data on weekly frequency and daily amount of consumption of alcoholic beverages. Then alcohol drinking was categorized to never-drinker, < 20, 20–40, > 40 g-ethanol/day, equivalent to < 1, 1 to 2, > 2 go of Japanese sake per day [21].

This study was approved by the Institutional Review Board for Clinical Research in Tokai University (20R369) and the Hitachi Review Board (2021–16).

Statistical analysis

Risk factors of Fib4 ≥ 2.67 in a cross-sectional setting

Fib4 index was calculated using the following formula [1]:

$${\text{Fib4 index}} = [{\text{Age}} \, ({\text{years}}) \times {\text{AST}}(U/L)]/[{\text{platelet}} \, (109/L) \times \surd {\text{ALT(U/L}}].$$

A Fib4 index of < 1.3, 1.3–2.67, or ≥ 2.67 was considered as a low, moderate, or high risk for fibrosis, respectively [22, 23]. The rate of patients with Fib4 ≥ 1.3 or ≥ 2.67 was calculated by age group.

In the data set of FY 2019, the odds ratios (ORs) and 95% confidence interval (CI) of the risk for Fib4 ≥ 2.67 (high risk) were calculated using the logistic model. The selected variables were liver dysfunction-related factors, such as body mass index (BMI), fatty liver detected by ultrasonography, abdominal condition, alcohol drinking, and GGT. According to a preliminary univariate analysis, HDL and LDL showed a significant association, thereby included as variables. Smoking history was also considered as a variable because of its association with fibrosis [2].

Risk factors of Fib4 ≥ 2.67 in a retrospective cohort setting

To identify the risk factors for the outcome of Fib4 ≥ 2.67 even once from FY2000 to FY2019 in the data set-2, we calculated the hazard ratio (HR) and 95% CI by using the COX proportional hazard model. In particular, we calculated the HR and 95% CI of the variables age, BMI, alcohol drinking history, GGT, HDL, and LDL as covariates, as examined in previous studies [5]. Finally, these variables were entered into the COX model. These variables from the data obtained in FY2010 and FY2019 were also entered. All statistical data were analyzed IBM-SPSS version 28.

Results

In the cross-sectional setting, Fig. 2A (I and II) illustrates the rate of patients with Fib4 ≥ 2.67 and ≥ 1.3 by ALT or AST abnormality. The percentage of Fib4 ≥ 2.67 in patients with both ALT and AST ≥ 40 IU/L per age group was 3%, 0%, 3%, 9%, 7%, 25%, 38%, and 45% in ≤ 39, 40–44, 40–45, 50–54, 55–60, 60–64, 65–69, and ≥ 70 years, respectively. Figure 2B shows the rate of patients with Fib4 ≥ 2.67 and ≥ 1.3 by smoking history (pack years) and diabetes mellitus (DM). The rate was not different in terms of the status of smoking history or present illness of DM. Figure 2C shows the rate of patients with Fib4 ≥ 2.67 or ≥ 1.3 by alcohol drinking and GGT. The Fib4 ≥ 2.67 rate was strictly elevated in heavy drinkers (≥ 40 g/day) aged over 65 years. Meanwhile, the Fib4 ≥ 1.3 rate increased with each daily alcohol intake. Furthermore, the GGT ≥ 200 IU/L rate increased among patients aged > 55 years. Figure 2D shows the rate of patients with Fib4 ≥ 2.67 or ≥ 1.3 by BMI and fatty liver presence. In the age group of > 60 years, the Fib4 ≥ 2.67 rate was higher in those with a BMI ≥ 30 kg/m2. However, the rate was not different in terms of the fatty liver status. Figure 2E shows the rate of patients with Fib4 ≥ 2.67 or ≥ 1.3 by HDL and LDL. Interestingly, the rate of FIb4 ≥ 2.67 increased dose dependently in those with high HDL and low LDL.

Fig. 2
figure 2figure 2figure 2figure 2

A Rate of patients with Fib4 ≥ 2.67 (I) or ≥ 1.3 (II) by each status of ALT and AST abnormalities. Blue, orange, and red line presents ‘with normal limit (WNL),’ ‘ALT ≥ 40 (IU/l) or AST ≥ 40 (IU/l),’ and ‘ALT ≥ 40 (IU/l) and AST ≥ 40 (IU/l),’ respectively. B Rate of patients with Fib4 ≥ 2.67 (I) or ≥ 1.3 (II) by each status of smoking and that with Fib4 ≥ 2.67 (III) or ≥ 1.3 (IV) by each current status of DM (diabetes mellitus). In (I) and (II), blue, orange, gray, yellow, or dark blue line presents ‘none of smoking habit,’ ‘ < 20 pack-year,’ ‘20–29 pack-year,’ ‘30–39 pack-year,’ and ≥ ‘40 pack-year,’ respectively. In (III) and (IV), blue or orange line presents ‘no present history of DM’ or ‘present history of DM,’ respectively. C Rate of patients with Fib4 ≥ 2.67 (I) or ≥ 1.3 (II) by each status of alcohol drinking and that with Fib4 ≥ 2.67 (III) or ≥ 1.3 (IV) by each status of GGT. In (I) and (II), blue, orange, gray, or red line presents ‘no habit of alcohol drinking,’ ‘ < 20 g (ethanol)/day,’ ‘20 ≤ habit of alcohol drinking < 40,’ or ‘habit of alcohol drinking ≥ 40 g,’ respectively. In III) and IV), blue, orange, gray, or red line presents ‘GGT < 40 (U/l),’ ‘40 ≤ GGT < 70,’ ‘70 ≤ GGT < 200,’ or ‘GGT ≥ 200,’ respectively. D Rate of patients with Fib4 ≥ 2.67 (I) or ≥ 1.3 (II) by each status of BMI and that with Fib4 ≥ 2.67 (III) or ≥ 1.3 (IV) by each status of fatty liver. In (I) and (II), blue, green, yellow, or red line presents ‘BMI < 18.5 (kg/m2),’ ‘18.5 ≤ BMI < 25,’ ‘25 ≤ BMI < 30,’ or ‘ BMI ≥ 30,’ respectively. In (III) and (IV), blue or orange line presents ‘none of fatty liver’ or ‘present of fatty liver,’ respectively. E Rate of patients with Fib4 ≥ 2.67 (I) or ≥ 1.3 (II) by each status of HDL, and that with Fib4 ≥ 2.67 (III) or ≥ 1.3 (IV) by each status of LDL. In (I) and (II), blue, orange or red line presents ‘HDL < 40 (mg/dl),’ ‘40 ≤ HDL < 70,’ or ‘HDL ≥ 70,’ respectively. In (III) and (IV), red, orange or blue line presents ‘LDL < 120 (mg/dl),’ ‘120 ≤ LDL < 160,’ or ‘LDL ≥ 160,’ respectively

Full size image

The OR of the risk for Fib4 ≥ 2.67 was calculated by logistic regression, and Table 1 lists the results. In the table, models 1 and 2 show the alcohol drinking and GGT results. The risk for Fib4 ≥ 2.67 was high in heavy alcohol drinkers (OR = 3.21, 95% CI = 1.38–7.44) but considerably high in patients with GGT ≥ 200 (OR = 29.05, 95% CI = 17.03–49.56). The crude OR of HDL ≥ 70 was 2.32 (95% CI = 1.23–4.39), referred to as HDL < 40. A higher HDL showed an increased risk in the univariate analysis, but the risk was not significant in the multivariate analysis. Regarding LDL, the OR of LDL ≥ 160 was 0.35 (95% CI = 0.16–0.77), referred to as LDL ≥ 120.

Table 1 Odds ratio of the risk for FIB4 index ≥ 2.67 calculated by logistic methods
Full size table

Figure 3 shows the results of the retrospective cohort setting obtained by using the COX proportional model. Number of subjects who could be followed up is shown in Additional file 1: Table S1. Figure 3A demonstrates the accumulating rate of Fib4 ≥ 2.67 in terms of alcohol drinking and GGT. The HR was adjusted with age, BMI, HDL, and LDL. Additional file 1: Tables S2 and S3 list the detailed information. The HR of alcohol drinking at 20–40 and ≥ 40 g/day was 1.63 (95% CI = 1.32–2.17) and 2.17 (1.58–2.98), respectively. The HR is also shown in the information obtained at FY2010 and FY2019. The association between alcohol drinking and the Fib4 ≥ 2.67 rate did not change from baseline using the information after 10 and 20 years. However, the relationship of the Fib4 ≥ 2.67 rate with GGT differed. The HRs of those with a high GGT value (≥ 200 IU/L) at baseline, 10 years, and 20 years later were 3.57 (95%CI = 2.36–5.41), 7.65 (95%CI = 5.65–111.12), and 6.04 (95% CI = 3.35–10.91), respectively. Thus, the rate of Fib4 ≥ 2.67 sharply increased among those with a high GGT value (≥ 200) at 10 years after the baseline (Fig. 3A-II).

Fig. 3
figure 3figure 3figure 3

Accumulating rate of Fib4 ≥ 2.67 by Cox analysis. A Accumulating rate of Fib4 ≥ 2.67 by each status of alcohol drinking (I) and GGT (II) at baseline (FY2000), FY2010, and FY2019). In (I), blue, green, purple, or orange line presents ‘no habit of alcohol drinking, ‘ < 20 g (ethanol)/day,’ ‘20–39 g,’ or ‘ ≥ 40 g,’ respectively. In (II), blue, green, purple, or orange line presents ‘GGT < 40 (IU/l),’ ‘40 ≤ GGT < 70,’ ‘70 ≤ GGT < 200,’ or ‘GGT ≥ 200,’ respectively. B Accumulating rate of Fib4 ≥ 2.67 by each status of BMI (I) and delta-BMI (II) at baseline (FY2000), FY2010, and FY2019). In (I), blue, green, purple, or orange line presents ‘BMI < 18.5 (kg/m2),’ ‘18.5 ≤ BMI < 25,’ ‘25 ≤ BMI < 30,’ or ‘ BMI ≥ 30,’ respectively. In (II), blue, green, or purple line presents ‘ delta-BMI < − 1 (kg/m2),’ ‘ − 1 ≤ delta-BMI <  + 2,’ or ‘ BMI ≥  + 2,’ respectively. C Accumulating rate of Fib4 ≥ 2.67 by each status of HDL (I) and LDL (II) at baseline (FY2000), FY2010, and FY2019). In (I), blue, purple, or green line presents ‘ HDL < 40 (mg/dl),’ ‘ 40 ≤ HDL < 70,’ or ‘ HDL ≥ 70,’ respectively. In (II), green, purple, or blue line presents ‘ LDL < 120 (mg/dl),’ ‘ 120 ≤ LDL < 160,’ or ‘ LDL ≥ 160,’ respectively

Full size image

Figure 3B shows the accumulating rate of Fib4 ≥ 2.67 by the status of BMI and change of BMI (delta-BMI). The HR was adjusted with age, HDL, LDL, and GGT, and detailed information is shown in Additional file 1: Tables S4 and S5. Patients with BMI ≥ 30 kg/m2 at baseline or 10 years later had a higher rate of Fib4 ≥ 2.67, but after 20 years, the relationship was no longer observed. In BMI fluctuation, the rate of Fib4 ≥ 2.67 was higher in those who had a BMI decreased by − 1 or less until 10 years after the baseline.

Figure 3C shows the accumulating rate of Fib4 ≥ 2.67 by the status of HDL and LDL. The rate was adjusted with age, BMI, and GGT, and detailed information is shown in Additional file 1: Tables S6 and S7. When HDL > 70 or LDL ≤ 120, the HR of Fib4 ≥ 2.67 was high. In both HDL and LDL cases, the association was seen in a dose-dependent manner. The analysis including or excluding patients with dyslipidemia did not affect the results.

The concordance rate of each category using the kappa value between 4 categories of alcohol drinking habits and 4 categories of GGT at FY2000, FY2010, and FY2019 was 0.081, 0.079, and 0.073, respectively. The concordance rates were 0.476 and 0.421 between alcohol drinking at FY2000 and that at FY2010 and between alcohol drinking at FY2000 and that at FY2019, respectively (Tables 2, 3, 4).

Table 2 Cross table of alcohol drinking and GGT at FY2000, FY2010, and FY2019
Full size table
Table 3 Cross table of alcohol drinking at baseline, at FY2010, and FY2019
Full size table
Table 4 Cross table of GGT at baseline, at FY2010, and FY2019
Full size table

Discussion

This study demonstrated that Fib4 could be an effect marker in identifying patients who need assessment for ALD by using GGT at the same time as an exposure and effect marker for estimating alcohol consumption. In ALD, the AST/ALT ratio increases and platelets decrease as liver fibrosis progresses [8]; thus, theoretically, Fib4 could be an effect marker. In this study, when GGT exceeded 200 IU/L in a group of patients after 10 years, the rate of Fib4 ≥ 2.67 considerably elevated. Currently, it is unlikely that an examinee will consult a hepatologist solely due to a high GGT on health examinations. If future clinical studies reveal alcoholic parenchymal damage in the livers of patients with elevated levels of both Fib4 and GGT, a follow-up program for subjects with high GGT values would be developed.

In this study, although high BMI (≥ 30 kg/m2) indicated a risk for Fib4 elevation, our results showed a difference between such risk and the status of fatty liver, and Fib4 values were higher in those who lost weight than in those who gained weight. According to our results and recent findings [7], Fib4 may be difficult to interpret for NAFLD in the general population. NAFLD is defined as the consumption of ≤ 30 g of alcohol per day [22], but in the case of alcoholic liver injury, ≥ 60 g is consumed [22]. During our study period, numerous male workers consumed alcohol at 30–60 g/day, and their health management is also important. Fib4 seems to have a significance as a marker for liver fibrosis because of the addition of platelet levels. Liver function tests, including ALT, AST, and GGT, are strongly associated with fatty liver in conjunction with metabolic syndrome [24] or ALD [8]. Considering that the prevalence of viral hepatitis has reduced [25], the interest has now shifted to NASH [22]. In addition, ALD is categorized as addiction and is treated by a special psychiatric field. From these points, ALD at a mild stage is definitely overlooked [8].

GGT increases not only by alcohol consumption but also by metabolic syndrome and enzyme-inducing drugs [13]. Baseline GGT level is positively and strongly associated with the risk for metabolic syndrome in a nonlinear dose–response manner [26, 27]. Several epidemiologic studies have also demonstrated important advances in the definition of the associations between serum GGT level and the risk of overall mortality, coronary heart disease, type 2 DM, stroke, and chronic kidney disease [12, 28,29,30]. The regulatory mechanism of GGT expression has been already been widely investigated. In addition, the 5′‐untranslated regions of mRNAs of the enzyme differ in a tissue‐specific manner but share a common protein-coding region, and the tissue‐specific and developmental stage-specific expression, as well as hepatic induction, is conferred by different promoters [31]. By light microscopy, alcoholic liver samples had a marked GGT activity in the bile canaliculi and a diffuse activity in the cytoplasm [32]. Recently, the GGT/albumin ratio included gamma‐glutamyl transpeptidase, and albumin is a novel inflammatory marker [33]. These findings on GGT are mainly involved in glutathione metabolism and cellular protection against oxidative damage [13].

This study also found interesting results in lipid metabolism. For instance, Fib4 is associated with dyslipidemia. Thus, we excluded patients with medication for dyslipidemia. Low HDL-C has been associated with NAFLD and end-stage hepatitis [34, 35]. Recently, the total cholesterol/HDL-C ratio was reported to be a predictive marker of NAFLD [36], and the triglyceride/HDL-C ratio as a predictive marker of metabolic-associated fatty liver disease (MAFLD) [37]. While the current study found that Fib4 increment positively correlated with HDL-C, a previous study reported an inverse relationship between Fib4 and GGT/HDL ratio, which increases with MAFLD [38]. One possible reason for these phenomena is the inadequate model-based statistical adjustment for alcohol consumption, which can elevate HDL-C; HDL-C is known to be an objective maker for alcohol consumption, independent of self-report [39, 40]. According to our findings, Fib4 might be associated with the risk of liver disease by alcoholic consumption.

In ALD, alcoholic hepatitis progresses to alcoholic steatohepatitis, leading to cirrhosis in some patients. The vast majority (90–100%) of chronic heavy drinkers develop alcoholic fatty liver disease. However, only 10–20% develop advanced ALD, and individual differences in its susceptibility for ALD are still poorly understood [8]. Although GGT levels are associated with alcohol consumption, the reported levels only correlate moderately with alcohol consumption (r = 0.30–0.40 in males, 0.15–0.30 in females); additionally, GGT level elevation is different between individuals with the same amount of alcohol consumed [41]. In the present study, the kappa value between the self-report of alcohol drinking and the serum level of GGT was very low (0.081). However, as mentioned above, GGT elevation indicates a risk for liver-related mortality [29]. Thus, GGT (GGT responder) increase may be a good marker of individual susceptibility for liver damage by oxidative stress, including the alcohol metabolism in ALD. However, only GGT abnormalities are found in health examinations, and any follow-up measures have not been established. Clinically clarifying the relationship between Fib4, GGT, and ALD would increase the significance of GGT measurement in health examinations.

Patients with ALD have been treated mainly by addiction specialists in the psychiatric field as alcohol dependence. Recently, harm reduction by reducing alcohol consumption, which has been used as a treatment approach in Europe [42], has gained recognition in Japan [43]. Treatment with anti-alcohol drugs, such as nalmefene, has also advanced [44], and it can be prescribed not only by specialized psychiatrists but also by hepatologists. Therefore, when ALD is suspected from the health examination results, patients must be actively recommended to seek consultation to hepatologists. In this study, analysis was performed using threshold values of 2.67 for Fib4 [23] and 200 IU/L for GGT; nevertheless, it will be necessary in the future to examine these cutoff values among general workers.

Regarding the strength of this study, it was verified by a cross-sectional study and a 20-year longitudinal study. However, given that the limitation is a follow-up survey in the workplace, selection bias is possible because a healthy-worker effect cannot be denied. In addition, although GGT ≥ 200 IU/L and Fib4 ≥ 2.67 are proposed, clinical studies are required in this respect. Additionally, clinically elastorgraphy verification, histopathological examinations, and investigation on long-term outcomes should be conducted.

In conclusion, Fib4 combined with GGT could be a useful effect marker for alcoholic liver injury. Although the examinee does not often refer to a hepatologist merely because GGT is high in health examinations, liver parenchymal injury might be considered if both Fib4 and GGT increase. On the basis of our result, we proposed that alcoholic liver injury occurs if the GGT value exceeds 200 IU/L and Fib4 is 2.67 or more. Thus, Fib4 could be an effect marker on alcoholic liver injury, together with GGT in health examinations. However, further clinical evaluation studies are required.

Availability of data and materials

The data sets during and/or analyzed during the current study available from the corresponding author on reasonable request.

Abbreviations

PI:

Present illness

PH:

Past history

FY:

Fiscal year

Fib4:

Fib4 index

AST:

Aspartate aminotransferase

ALT:

Alanine aminotransferase

NAFLD:

Nonalcoholic fatty liver disease

NAFL:

Nonalcoholic fatty liver

NASH:

Nonalcoholic steatohepatitis

HCC:

Hepatocellular carcinoma

ALD:

Alcoholic liver disease

HDL:

High-density lipoprotein cholesterol

LDL:

Low-density lipoprotein cholesterol

GGT:

Gamma-glutamyl transferase

OR:

Odds ratio

ORs:

Odds ratios

CI:

95% Confidence interval

BMI:

Body mass index

HR:

Hazard ratio

DM:

Diabetes mellitus

MAFLD:

Metabolic-associated fatty liver disease

References

  1. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Mark SS, Torriani FJ, Dieterich DT, Thomas DL, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.

    Article  CAS  Google Scholar 

  2. Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578–88.

    Article  Google Scholar 

  3. Balakrishnan M, Loomba R. The role of noninvasive tests for differentiating NASH From NAFL and diagnosing advanced fibrosis among patients with NAFLD. J Clin Gastroenterol. 2020;54(2):107–13.

    Article  Google Scholar 

  4. Kechagias S, Ekstedt M, Simonsson C, Nasr P. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones (Athens). 2022.

  5. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486–501.

    Article  CAS  Google Scholar 

  6. Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, Aboyans V, Adetokunboh O, Afshin A, Agrawal A, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017;390(10100):1151–210.

    Article  Google Scholar 

  7. Sugiyama A, Kurisu A, E B, Ouoba S, Ko K, Rakhimov A, Akita T, Harakawa T, Sako T, Koshiyama M et al. Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups. BMC Gastroenterol. 2022, 22(1):241.

  8. Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16.

    Article  Google Scholar 

  9. Kamper-Jørgensen M, Grønbaek M, Tolstrup J, Becker U. Alcohol and cirrhosis: dose–response or threshold effect? J Hepatol. 2004;41(1):25–30.

    Article  Google Scholar 

  10. Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med. 2004;38(5):613–9.

    Article  Google Scholar 

  11. Popham RE, Schmidt W. Words and deeds: the validity of self-report data on alcohol consumption. J Stud Alcohol. 1981;42(3):355–68.

    Article  CAS  Google Scholar 

  12. Watson CG, Tilleskjor C, Hoodecheck-Schow EA, Pucel J, Jacobs L. Do alcoholics give valid self-reports? J Stud Alcohol. 1984;45(4):344–8.

    Article  CAS  Google Scholar 

  13. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38(4):263–355.

    Article  CAS  Google Scholar 

  14. Scouller K, Conigrave KM, Macaskill P, Irwig L, Whitfield JB. Should we use carbohydrate-deficient transferrin instead of gamma-glutamyltransferase for detecting problem drinkers? A systematic review and metaanalysis. Clin Chem. 2000;46(12):1894–902.

    Article  CAS  Google Scholar 

  15. Sakaguchi S, Takahashi S, Sasaki T, Kumagai T, Nagata K. Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress. Drug Metab Pharmacokinet. 2011;26(1):30–46.

    Article  CAS  Google Scholar 

  16. Fukai K, Terauchi R, Noro T, Ogawa S, Watanabe T, Nakagawa T, Honda T, Watanabe Y, Furuya Y, Hayashi T, et al. Real-time risk score for glaucoma mass screening by spectral domain optical coherence tomography: development and validation. Transl Vis Sci Technol. 2022;11(8):8.

    Article  Google Scholar 

  17. Honda T, Nakagawa T, Watanabe Y, Hayashi T, Nakano T, Horie S, Tatemichi M. Association between information and communication technology use and ocular axial length elongation among middle-aged male workers. Sci Rep. 2019;9(1):17489.

    Article  Google Scholar 

  18. Nakano T, Hayashi T, Nakagawa T, Honda T, Owada S, Endo H, Tatemichi M. Applicability of automatic spectral domain optical coherence tomography for glaucoma mass screening. Clin Ophthalmol. 2017;11:97–103.

    Article  Google Scholar 

  19. Nakano T, Hayashi T, Nakagawa T, Honda T, Owada S, Endo H, Tatemichi M. Increased incidence of visual field abnormalities as determined by frequency doubling technology perimetry in high computer users among Japanese workers: a retrospective cohort study. J Epidemiol. 2018;28(4):214–9.

    Article  Google Scholar 

  20. Watanabe Y, Nakagawa T, Fukai K, Honda T, Furuya H, Hayashi T, Tatemichi M. Descriptive study of chest x-ray examination in mandatory annual health examinations at the workplace in Japan. PLoS ONE. 2022;17(1): e0262404.

    Article  CAS  Google Scholar 

  21. Fukai K, Kuwahara K, Chen S, Eguchi M, Kochi T, Kabe I, Mizoue T. The association of leisure-time physical activity and walking during commuting to work with depressive symptoms among Japanese workers: a cross-sectional study. J Occup Health. 2020;62(1): e12120.

    Article  Google Scholar 

  22. Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50(4):364–77.

    Article  Google Scholar 

  23. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–12.

    Article  CAS  Google Scholar 

  24. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9.

    Article  Google Scholar 

  25. Tanaka J, Kurisu A, Ohara M, Ouoba S, Ohisa M, Sugiyama A, Wang ML, Hiebert L, Kanto T, Akita T. Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: a simulation study. Lancet Reg Health West Pac. 2022;22: 100428.

    Article  Google Scholar 

  26. Ma Q, Liao X, Shao C, Lin Y, Wu T, Sun Y, Feng ST, Ye J, Zhong B. Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease. BMC Gastroenterol. 2021;21(1):215.

    Article  Google Scholar 

  27. Kunutsor SK, Apekey TA, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: a systematic review and dose-response meta-analysis. Int J Clin Pract. 2015;69(1):136–44.

    Article  CAS  Google Scholar 

  28. Kim YG, Han K, Jeong JH, Roh SY, Choi YY, Min K, Shim J, Choi JI, Kim YH. Metabolic syndrome, gamma-glutamyl transferase, and risk of sudden cardiac death. J Clin Med. 2022; 11(7).

  29. Ho FK, Ferguson LD, Celis-Morales CA, Gray SR, Forrest E, Alazawi W, Gill JM, Katikireddi SV, Cleland JG, Welsh P, et al. Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: a prospective cohort study in the UK Biobank. EClinicalMedicine. 2022;48: 101435.

    Article  Google Scholar 

  30. Li S, Wang A, Tian X, Zuo Y, Meng X, Zhang Y. Elevated gamma-glutamyl transferase levels are associated with stroke recurrence after acute ischemic stroke or transient ischemic attack. CNS Neurosci Ther. 2022.

  31. Ikeda Y, Taniguchi N. Gene expression of gamma-glutamyltranspeptidase. Methods Enzymol. 2005;401:408–25.

    Article  CAS  Google Scholar 

  32. Ishii H, Ebihara Y, Okuno F, Munakata Y, Takagi T, Arai M, Shigeta S, Tsuchiya M. Gamma-Glutamyl transpeptidase activity in liver of alcoholics and its localization. Alcohol Clin Exp Res. 1986;10(1):81–5.

    Article  CAS  Google Scholar 

  33. Li H, Liu R, Li J, Li J, Wu H, Wang G, Li Z, Li D. Prognostic significance of gamma-glutamyl transpeptidase to albumin ratio in patients with intrahepatic cholangiocarcinoma after hepatectomy. J Cell Mol Med. 2022;26(11):3196–202.

    Article  CAS  Google Scholar 

  34. Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020;42: 101092.

    Article  CAS  Google Scholar 

  35. Wang Y, Shen W, Huang F, Yu C, Xi L, Gao J, Yin M, Liu X, Lin J, Liu L, et al. HDL-C levels added to the MELD score improves 30-day mortality prediction in Asian patients with cirrhosis. J Int Med Res. 2022;50(7):3000605221109385.

    Article  CAS  Google Scholar 

  36. Ren XY, Shi D, Ding J, Cheng ZY, Li HY, Li JS, Pu HQ, Yang AM, He CL, Zhang JP, et al. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study. Lipids Health Dis. 2019;18(1):47.

    Article  Google Scholar 

  37. Liu Z, He H, Dai Y, Yang L, Liao S, An Z, Li S. Comparison of the diagnostic value between triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio in metabolic-associated fatty liver disease patients: a retrospective cross-sectional study. Lipids Health Dis. 2022;21(1):55.

    Article  CAS  Google Scholar 

  38. Xing Y, Chen J, Liu J, Ma H. Associations between GGT/HDL and MAFLD: a cross-sectional study. Diabetes Metab Syndr Obes. 2022;15:383–94.

    Article  CAS  Google Scholar 

  39. Berger D, Williams EC, Bryson CL, Rubinsky AD, Bradley KA. Alcohol questionnaires and HDL: screening scores as scaled markers of alcohol consumption. Alcohol. 2013;47(6):439–45.

    Article  Google Scholar 

  40. Høiseth G, Hilberg T, Trydal T, Husa A, Vindenes V, Bogstrand ST. The alcohol marker phosphatidylethanol is closely related to AST, GGT, ferritin and HDL-C. Basic Clin Pharmacol Toxicol. 2022;130(1):182–90.

    Article  Google Scholar 

  41. Sillanaukee P, Massot N, Jousilahti P, Vartiainen E, Sundvall J, Olsson U, Poikolainen K, Pönniö M, Allen JP, Alho H. Dose response of laboratory markers to alcohol consumption in a general population. Am J Epidemiol. 2000;152(8):747–51.

    Article  CAS  Google Scholar 

  42. Kiefer F, Batra A, Petersen KU, Ardern IS, Tananska D, Bischof G, Funke W, Lindenmeyer J, Mueller S, Preuss UW, et al. German guidelines on screening, diagnosis, and treatment of alcohol use disorders: update 2021. Eur Addict Res. 2022;28(4):309–22.

    Article  Google Scholar 

  43. New guidelines for the diagnosis and treatment of alcohol and drug use disorders Shinko Igaku Shuppansha.; 2018.

  44. Miyata H, Takahashi M, Murai Y, Tsuneyoshi K, Hayashi T, Meulien D, Sørensen P, Higuchi S. Nalmefene in alcohol-dependent patients with a high drinking risk: randomized controlled trial. Psychiatry Clin Neurosci. 2019;73(11):697–706.

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by the Ministry of Health, Labour and Welfare, Japan (Grant number: 20HC1004). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or /and decision to submit the manuscript for publication.

Author information

Author notes

  1. Takeshi Hayashi

    Present address: Occupational Hygiene and Promotion Center, Hitachi, Ltd, Tokyo, Japan

Authors and Affiliations

  1. Hitachi General Hospital, Hitachi, Japan

    Hideki Shinoda

  2. Hitachi Health Care Center, Hitachi, Japan

    Yuya Watanabe, Kayoko Kasuya, Toru Honda & Toru Nakagawa

  3. Department of Preventive Medicine, Tokai University School of Medicine, Isehara, Japan

    Kota Fukai, Yuko Furuya, Shoko Nakazawa & Masayuki Tatemichi

  4. Hepatitis Information Centre, Research Centre for Hepatitis and Immunology, National Centre for Global Health and Medicine, Ichikawa, Japan

    Masaaki Korenaga

Authors
  1. Hideki Shinoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuya Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kota Fukai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kayoko Kasuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuko Furuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shoko Nakazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toru Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takeshi Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toru Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masayuki Tatemichi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masaaki Korenaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Y.W, T.H, T.N, and T.H collected the data. F.Y performed data cleaning. K.K, K.F, F.Y, M.K, and M.T. designed this study and K.K, K.F, F.Y, and M.T analyzed the data. H.S, Y.W, and M.T wrote the manuscript paper. M.K. M.T, and H.T supervised this study and provided critical comments. All the authors have reviewed, read, and approved the final manuscript.

Corresponding author

Correspondence to Kota Fukai.

Ethics declarations

Ethics approval and consent to participate

This study was conducted with the approval of the Institutional Review Board for Clinical Research, Tokai University (20R369), and Hitachi Review Board (2016–2021). Informed consent was obtained by opt-out method.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Number of follow-up. Table S2. Hazard ratio calculated by COX model for Fib4 index ≥ 2.67 using information on alcohol drinking habits at baseline, FY2010, and Fy2019. Table S3. Hazard ratio calculated by COX model for Fib4 index ≥ 2.67 using information on GGT at baseline, FY2010, and Fy2019. Table S4. Hazard ratio calculated by COX model for Fib4 index ≥ 2.67 using information on BMI at baseline, FY2010, and Fy2019. Table S5. Hazard ratio calculated by COX model for Fib4 index ≥ 2.67 using information on change of BMI at baseline, FY2010, and Fy2019. Table S6. Hazard ratio calculated by COX model for Fib4 index ≥ 2.67 using information on HDL at baseline, FY2010, and Fy2019. Table S7. Hazard ratio calculated by COX model for Fib4 index ≥ 2.67 using information on HDL at baseline, FY2010, and Fy2019.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shinoda, H., Watanabe, Y., Fukai, K. et al. Significance of Fib4 index as an indicator of alcoholic hepatotoxicity in health examinations among Japanese male workers: a cross-sectional and retrospectively longitudinal study. Eur J Med Res 28, 31 (2023). https://doi.org/10.1186/s40001-022-00976-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40001-022-00976-6

Keywords

European Journal of Medical Research

ISSN: 2047-783X

Contact us